Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Amifostine for Multiple Myeloma with Dr. William Bensinger

Amifostine for Multiple Myeloma with Dr. William Bensinger

Dr. William Bensinger shares the results of a clinical study that was presented at the 54th ASH Annual Meeting and Exposition. For some time, Dr. Bensinger has been interested in the use of amifostine, a drug which has been around for over 35 years and has been used to help protect patients from the toxicity of various treatments. Dr. Bensinger wanted to find out if amifostine could help protect patients from the toxicity of higher-dose melphalan treatments. The study found that who took amfostine were able to tolerate the higher doses of melphalan and also experience a higher response rate than those who took just the standard dose of melphalan.

Related Videos

ASH 2012 Multiple Myeloma Update with Dr. William Bensinger

In this interview from the 2012 American Society of Hematology (ASH) Annual Meeting, Dr. William Bensinger discusses the drug combination of Carfilzomib, Pomalidomide, and Dexamethasone. He explains the history and use of these drugs and how they were used in a phase one trial. The study gives patients less toxic therapy, a combination of more powerful medicines, and new hope. Learn more about this combination therapy for multiple myeloma.

Therapies for Myeloma Patients After Relapse with Dr. William Bensinger

Dr. William Bensinger discusses therapies to treat multiple myeloma after relapse with Andrew Schorr from Patient Power at the American Society of Hematology (ASH) annual meeting in 2012. Dr. Bensinger talks about the controversial role of allogeneic transplants to treat myeloma patients. He also discusses drugs, such as lenalidomide, that have shown promising results for relapse patients.

Multiple Myeloma Testing and Personalized Treatment

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger and Dr. Noopur Raje discuss testing for the treatment of myeloma with Andrew Schorr from Patient Power. With the heterogeneity of the disease, adjusting the drug schedule and combination for the individual patient is the key to treatment efficacy and the control of side effects. Dr. Raje describes the panel of tests used to determine the appropriate individualized treatment regimen.

Multiple Myeloma Treatment and Research

In this video from our ""Living Well With Multiple Myeloma"" event held at SCCA in November 2011, Drs. William Bensinger of Seattle Cancer Care Alliance, and Noopur Raje of Massachusetts General Hospital discuss treatment and research for multiple myeloma with Andrew Schorr from Patient Power. Dr. Raje, who researches drugs that can help with the bone complications of myeloma, states that they are able to decrease the risk of fractures by about 50% with bisphosphonates. She also discusses a clinical trial which uses osteoblasts to promote bone healing. In the more than 20 years that Dr. Bensinger has studied myeloma, he has never been more hopeful about his ability to fight the disease. Proteasome inhibitors such as bortezomib have dramatically changed the landscape. Remissions have lasted longer and patients have lived longer as a result of these drugs. Learn more about advancements in treatment of myeloma.